Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
The Journal of Urology
|
October 2, 2012
The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial
Robert L Grubb, Gerald L Andriole, Matthew C Somerville, et al.
Advances in Experimental Medicine and Biology
|
June 5, 2004
Virtual reality surgical simulation for lower urinary tract endourologic surgery
Michael J Manyak, Kristin Santangelo, James Hahn, et al.
Journal of Endourology
|
May 25, 2002
Virtual reality surgical simulation for lower urinary tract endoscopy and procedures
Michael J Manyak, Kristin Santangelo, James Hahn, et al.
Studies in Health Technology and Informatics
|
October 2, 2004
Cryotherapy simulator for localized prostate cancer
James K Hahn, Michael J Manyak, Ge Jin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 7, 2015
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer
Franklin M Chu, Oliver Sartor, Leonard Gomella, et al.
International Journal of Clinical Practice
|
January 14, 2020
Men's Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo-controlled study
Claus G Roehrborn, Raymond C Rosen, Michael J Manyak, et al.
International Journal of Clinical Practice
|
October 15, 2018
Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-controlled study
Raymond C Rosen, Claus G Roehrborn, Michael J Manyak, et al.
World Journal of Urology
|
June 24, 2016
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, et al.
Journal of Endourology
|
March 14, 2002
Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy
Michael J Manyak, Stacey J Ackerman, Michael L Blute, et al.
BJU International
|
January 8, 2015
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
The Journal of Urology
|
October 2, 2012
The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial
Robert L Grubb, Gerald L Andriole, Matthew C Somerville, et al.
Advances in Experimental Medicine and Biology
|
June 5, 2004
Virtual reality surgical simulation for lower urinary tract endourologic surgery
Michael J Manyak, Kristin Santangelo, James Hahn, et al.
Journal of Endourology
|
May 25, 2002
Virtual reality surgical simulation for lower urinary tract endoscopy and procedures
Michael J Manyak, Kristin Santangelo, James Hahn, et al.
Studies in Health Technology and Informatics
|
October 2, 2004
Cryotherapy simulator for localized prostate cancer
James K Hahn, Michael J Manyak, Ge Jin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 7, 2015
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer
Franklin M Chu, Oliver Sartor, Leonard Gomella, et al.
International Journal of Clinical Practice
|
January 14, 2020
Men's Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo-controlled study
Claus G Roehrborn, Raymond C Rosen, Michael J Manyak, et al.
International Journal of Clinical Practice
|
October 15, 2018
Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-controlled study
Raymond C Rosen, Claus G Roehrborn, Michael J Manyak, et al.
World Journal of Urology
|
June 24, 2016
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, et al.
Journal of Endourology
|
March 14, 2002
Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy
Michael J Manyak, Stacey J Ackerman, Michael L Blute, et al.
BJU International
|
January 8, 2015
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, et al.
Page
of 3